Shares of Bellerophon Therapeutics Inc. (NASDAQ:BLPH) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price target of $7.67 for the company and are forecasting that the company will post ($0.42) earnings per share for the current quarter, according to Zacks. Zacks has also given Bellerophon Therapeutics an industry rank of 107 out of 265 based on the ratings given to its competitors.
Several equities research analysts have issued reports on the company. Zacks Investment Research cut Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Cowen and Company reissued a “buy” rating on shares of Bellerophon Therapeutics in a research note on Thursday, August 11th.
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) traded down 2.057% during mid-day trading on Friday, reaching $1.381. The company had a trading volume of 2,982 shares. The stock has a 50 day moving average of $1.50 and a 200-day moving average of $1.76. Bellerophon Therapeutics has a 52 week low of $1.09 and a 52 week high of $4.58. The company’s market capitalization is $20.16 million.
Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.12. On average, analysts expect that Bellerophon Therapeutics will post ($1.75) earnings per share for the current fiscal year.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.